Motley Fool Money cover image

Everything at Highs: Tech, Rates, Gold and Cocoa

Motley Fool Money

00:00

Vertex's Bold $5 Billion Move

This chapter explores Vertex Pharmaceuticals' substantial acquisition of Alpine Immune Sciences, focusing on its strategic importance and the potential impact on kidney autoimmune disease treatments. The discussion also highlights the risks involved with the acquisition and touches on unexpected profits from gold sales in retail.

Play episode from 27:58
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app